All Articles

In this ongoing phase 2 study, the efficacy of SHR-1316 plus IBI310 is being evaluated in patients with advanced intrahepatic cholangiocarcinoma after inadequate response to first-line therapy.

Dr Mahmood presented results from the largest multi-institutional review of efficacy outcomes following targeted agents in patients with cholangiocarcinoma.

In the phase 2 component of the phase 2/3 BEER-BTC study, bevacizumab plus erlotinib improved outcomes in patients with advanced biliary tract cancers.

Researchers investigated the efficacy and safety of neoadjuvant durvalumab plus gemcitabine/cisplatin (GemCis) versus GemCis alone in patients with biliary tract cancer.

In the ongoing phase 2 ADJUBIL study, the clinical activity of immunotherapies durvalumab and tremelimumab with or without capecitabine is being assessed in patients with resectable biliary tract cancer in the adjuvant setting.

This phase 2 basket study investigated the combination of tucatinib and trastuzumab as second-line treatment for patients with HER2-positive biliary tract cancer.

To improve survival in patients with biliary tract cancer, researchers are studying combinations of immunotherapy and poly-ADP ribose polymerase inhibitors; the BilT-02 study is summarized.

Researchers present preliminary findings from the HERIZON-BTC-01 study, which investigated zanidatamab’s efficacy in patients with HER2-positive biliary tract cancer.

In a subanalysis of the STAMP trial, circulating tumor DNA was assessed for its clinical effectiveness in detecting molecular residual disease in patients with cholangiocarcinoma.

In patients with biliary tract cancer, EGFR amplifications and FGFR3 fusions may serve as important predictive biomarkers and as potential targets for anticancer therapy in the future.